Publikationen der ALS-Forschungsgruppe an der Charité
Neurofilament light chain (NfL) – Biomarker für die ALS-Progression
Meyer T, Salkic E, Grehl T, Weyen U, Kettemann D, Weydt P,
Der Einsatz von Patient-reported Outcome Measures (PROM) und die Perspektive digitaler Biomarker bei der Amyotrophen Lateralsklerose
Maier A, Münch C, Meyer T. Klinische Neurophysiologie 2023; 54(01): 28-34. doi:
Acceptance of Enhanced Robotic Assistance Systems in People With Amyotrophic Lateral Sclerosis-Associated Motor Impairment: Observational Online Study
Maier A, Eicher C, Kiselev J, Klebbe R, Greuèl M, Kettemann D,
Remote digital assessment of amyotrophic lateral sclerosis functional rating scale – a multicenter observational study
Meyer T, Spittel S, Grehl T, Weyen U, Steinbach R, Kettemann D,
Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study
Maier A, Gaudlitz M, Grehl T, Weyen U, Steinbach R, Grosskreutz J,
Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany
Spittel S, Maier A, Kettemann D, Walter B, Koch B, Krause K,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis
Fernández-Santiago R, Hoenig S, Lichtner P,
Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop
Ludolph AC, Bendotti C, Blaugrund E,
Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect
Niemann S, Joos H, Meyer T,
The role of excitotoxicity in ALS – what is the evidence?
Ludolph AC, Meyer T, Riepe MW.J
Antiglutamate therapy of ALS – which is the next step?
Ludolph AC, Meyer T, Riepe MW.J
Molecular biology findings in amyotrophic lateral sclerosis
Bachus R, Claus A, Meyer T,
